Bernstein lowered the firm’s price target on Alnylam (ALNY) to $451 from $491 and keeps an Outperform rating on the shares. With topline results pre-announced in January, investor focus was squarely on forward commentary, the firm notes. Shares fell 4% as the company talked down Q1, seeming to confirm investor worries based on third party sales data, notes Bernstein, adding that it would be a buyer here.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY:
- 3 ‘Strong Buy’ Stocks to Buy Now, 2/13/2026, According to Top Analysts
- Alnylam price target lowered to $425 from $475 at Chardan
- Execution Risks Loom as Alnylam Races to Scale Global Operations for AMVUTTRA and 2030 Growth Ambitions
- Alnylam Pharmaceuticals: Amvuttra-Driven Profitability Inflection Supports Long-Term Growth and Buy Rating
- Alnylam Pharmaceuticals Projects Powerful Growth After Breakout Year